GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (NAS:INO) » Definitions » Cyclically Adjusted PS Ratio

Inovio Pharmaceuticals (Inovio Pharmaceuticals) Cyclically Adjusted PS Ratio : (As of Jun. 09, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Inovio Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Inovio Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Inovio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.84 27.98 16.59 5.05 1.81

Inovio Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.65 1.44 1.35 1.81 -

Competitive Comparison of Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Inovio Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Inovio Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Inovio Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Inovio Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.754 100.560 0.988
201409 0.364 100.428 0.478
201412 0.485 99.070 0.645
201503 1.018 99.621 1.347
201506 0.935 100.684 1.224
201509 3.924 100.392 5.151
201512 0.984 99.792 1.299
201603 1.347 100.470 1.767
201606 1.020 101.688 1.322
201609 2.039 101.861 2.638
201612 1.379 101.863 1.784
201703 1.676 102.862 2.147
201706 3.248 103.349 4.141
201709 0.364 104.136 0.461
201712 1.165 104.011 1.476
201803 0.203 105.290 0.254
201806 3.216 106.317 3.986
201809 0.260 106.507 0.322
201812 0.313 105.998 0.389
201903 0.348 107.251 0.428
201906 0.017 108.070 0.021
201909 0.101 108.329 0.123
201912 0.033 108.420 0.040
202003 0.128 108.902 0.155
202006 0.021 108.767 0.025
202009 0.016 109.815 0.019
202012 0.384 109.897 0.460
202103 0.022 111.754 0.026
202106 0.016 114.631 0.018
202109 0.017 115.734 0.019
202112 0.047 117.630 0.053
202203 0.011 121.301 0.012
202206 0.040 125.017 0.042
202209 0.441 125.227 0.464
202212 0.006 125.222 0.006
202303 0.005 127.348 0.005
202306 0.010 128.729 0.010
202309 0.017 129.860 0.017
202312 0.005 129.419 0.005
202403 0.000 131.776 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Inovio Pharmaceuticals  (NAS:INO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Inovio Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Inovio Pharmaceuticals (Inovio Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Executives
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
David B. Weiner director 717 BEACOM LANE, MERION STATION PA 19066-1603
Simon X Benito director 967 LAWRENCE AVE, WESTFIELD NJ 07090
Michael John Sumner officer: Chief Medical Officer 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Laurent Humeau officer: Chief Scientific Officer C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jacqueline Elizabeth Shea officer: Chief Operating Officer C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Peter Kies officer: CFO
Roger D Dansey director 21823 30TH DRIVE SE, BOTHELL WA 98021
Jong Joseph Kim director, officer: Chief Executive Officer 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jay Shepard director 15977 GRANDVIEW AVENUE, MONTE SERENO CA 95030
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Wendy L Yarno director
Morton Collins director
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Niranjan Sardesai officer: Chief Operating Officer VGX PHARMACEUTICALS, INC., 450 SENTRY PARKWAY, BLUE BELL PA 19422

Inovio Pharmaceuticals (Inovio Pharmaceuticals) Headlines